DCAT Value Chain Insights’ Production to Prescription
DCAT
52 episodes
1 week ago
Antibody drug conjugates (ADCs) are a niche but growing segment in the global bio/pharmaceutical industry—both on pipeline and market basis and in the CDMO sector. What are the growth prospects overall and in the major segments and how may evolving trade policy impact global supply lines? Gaurav Chaudhary, CEO, Roots Analysis, a business intelligence firm serving the bio/pharmaceutical industry, provides the latest market insights. Support the show
All content for DCAT Value Chain Insights’ Production to Prescription is the property of DCAT and is served directly from their servers
with no modification, redirects, or rehosting. The podcast is not affiliated with or endorsed by Podjoint in any way.
Antibody drug conjugates (ADCs) are a niche but growing segment in the global bio/pharmaceutical industry—both on pipeline and market basis and in the CDMO sector. What are the growth prospects overall and in the major segments and how may evolving trade policy impact global supply lines? Gaurav Chaudhary, CEO, Roots Analysis, a business intelligence firm serving the bio/pharmaceutical industry, provides the latest market insights. Support the show
API Alert: EU Proposes New Requirements To Secure Pharma Supply Chains
DCAT Value Chain Insights’ Production to Prescription
13 minutes
2 years ago
API Alert: EU Proposes New Requirements To Secure Pharma Supply Chains
The European Commission has issued its long-awaited proposal to reform pharmaceutical legislation in the EU, the first major overhaul in 20 years, which includes new requirements to address drug shortages and secure supply chains. For the text version of this article visit dcatvci.org. Key topics: (see Chapter Markers in drop down menu in audio player above) Proposed reforms Security of supply and supply-chain reforms Specific proposals Podcast Sponsor: BIOVECTRA Links:...
DCAT Value Chain Insights’ Production to Prescription
Antibody drug conjugates (ADCs) are a niche but growing segment in the global bio/pharmaceutical industry—both on pipeline and market basis and in the CDMO sector. What are the growth prospects overall and in the major segments and how may evolving trade policy impact global supply lines? Gaurav Chaudhary, CEO, Roots Analysis, a business intelligence firm serving the bio/pharmaceutical industry, provides the latest market insights. Support the show
